Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
75
XBI Quote, Financials, Valuation and Earnings
Last price:
$123.29
Seasonality move
:
4.35%
Day range:
$120.78 - $123.61
52-week range:
$66.66 - $123.61
Dividend yield:
0.03%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
11M
Avg. volume:
11.4M
1-year change:
24.76%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
|
XLV
State Street Health Care Select Sector SPDR ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XBI
State Street SPDR S&P Biotech ETF
|
$123.25 | -- | -- | -- | $0.03 | 0.03% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$212.83 | -- | -- | -- | $1.17 | 0.55% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$82.06 | -- | -- | -- | $0.23 | 0.49% | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
$89.39 | -- | -- | -- | $0.03 | 0.08% | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
$108.20 | -- | -- | -- | $0.07 | 0.24% | -- |
|
XLV
State Street Health Care Select Sector SPDR ETF
|
$153.90 | -- | -- | -- | $0.62 | 1.59% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | 1.273 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 0.657 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.859 | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | 1.031 | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | 0.960 | -- | -- |
|
XLV
State Street Health Care Select Sector SPDR ETF
|
-- | 0.326 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
|
XLV
State Street Health Care Select Sector SPDR ETF
|
-- | -- | -- | -- | -- | -- |
State Street SPDR S&P Biotech ETF vs. Competitors
-
Which has Higher Returns XBI or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to State Street SPDR S&P Biotech ETF's net margin of --. State Street SPDR S&P Biotech ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBIState Street SPDR S&P Biotech ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About XBI or FBT?
State Street SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Biotech ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe State Street SPDR S&P Biotech ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings XBIState Street SPDR S&P Biotech ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is XBI or FBT More Risky?
State Street SPDR S&P Biotech ETF has a beta of 0.931, which suggesting that the stock is 6.918% less volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.562%.
-
Which is a Better Dividend Stock XBI or FBT?
State Street SPDR S&P Biotech ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.03%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0.55% to investors and pays a quarterly dividend of $1.17 per share. State Street SPDR S&P Biotech ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or FBT?
State Street SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. State Street SPDR S&P Biotech ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, State Street SPDR S&P Biotech ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Biotech ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIState Street SPDR S&P Biotech ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns XBI or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to State Street SPDR S&P Biotech ETF's net margin of --. State Street SPDR S&P Biotech ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBIState Street SPDR S&P Biotech ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About XBI or PBE?
State Street SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Biotech ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe State Street SPDR S&P Biotech ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBIState Street SPDR S&P Biotech ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is XBI or PBE More Risky?
State Street SPDR S&P Biotech ETF has a beta of 0.931, which suggesting that the stock is 6.918% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.822, suggesting its less volatile than the S&P 500 by 17.787%.
-
Which is a Better Dividend Stock XBI or PBE?
State Street SPDR S&P Biotech ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.03%. Invesco Biotechnology & Genome ETF offers a yield of 0.49% to investors and pays a quarterly dividend of $0.23 per share. State Street SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or PBE?
State Street SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. State Street SPDR S&P Biotech ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, State Street SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Biotech ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIState Street SPDR S&P Biotech ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns XBI or XHE?
State Street SPDR S&P Health Care Equipment ETF has a net margin of -- compared to State Street SPDR S&P Biotech ETF's net margin of --. State Street SPDR S&P Biotech ETF's return on equity of -- beat State Street SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBIState Street SPDR S&P Biotech ETF-- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About XBI or XHE?
State Street SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Biotech ETF has higher upside potential than State Street SPDR S&P Health Care Equipment ETF, analysts believe State Street SPDR S&P Biotech ETF is more attractive than State Street SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBIState Street SPDR S&P Biotech ETF0 0 0 XHEState Street SPDR S&P Health Care Equipment ETF0 0 0 -
Is XBI or XHE More Risky?
State Street SPDR S&P Biotech ETF has a beta of 0.931, which suggesting that the stock is 6.918% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Equipment ETF has a beta of 1.125, suggesting its more volatile than the S&P 500 by 12.522%.
-
Which is a Better Dividend Stock XBI or XHE?
State Street SPDR S&P Biotech ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.03%. State Street SPDR S&P Health Care Equipment ETF offers a yield of 0.08% to investors and pays a quarterly dividend of $0.03 per share. State Street SPDR S&P Biotech ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or XHE?
State Street SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Equipment ETF quarterly revenues of --. State Street SPDR S&P Biotech ETF's net income of -- is lower than State Street SPDR S&P Health Care Equipment ETF's net income of --. Notably, State Street SPDR S&P Biotech ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Biotech ETF is -- versus -- for State Street SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIState Street SPDR S&P Biotech ETF-- -- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- --
-
Which has Higher Returns XBI or XHS?
State Street SPDR S&P Health Care Services ETF has a net margin of -- compared to State Street SPDR S&P Biotech ETF's net margin of --. State Street SPDR S&P Biotech ETF's return on equity of -- beat State Street SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBIState Street SPDR S&P Biotech ETF-- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About XBI or XHS?
State Street SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Biotech ETF has higher upside potential than State Street SPDR S&P Health Care Services ETF, analysts believe State Street SPDR S&P Biotech ETF is more attractive than State Street SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBIState Street SPDR S&P Biotech ETF0 0 0 XHSState Street SPDR S&P Health Care Services ETF0 0 0 -
Is XBI or XHS More Risky?
State Street SPDR S&P Biotech ETF has a beta of 0.931, which suggesting that the stock is 6.918% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Services ETF has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.625%.
-
Which is a Better Dividend Stock XBI or XHS?
State Street SPDR S&P Biotech ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.03%. State Street SPDR S&P Health Care Services ETF offers a yield of 0.24% to investors and pays a quarterly dividend of $0.07 per share. State Street SPDR S&P Biotech ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or XHS?
State Street SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Services ETF quarterly revenues of --. State Street SPDR S&P Biotech ETF's net income of -- is lower than State Street SPDR S&P Health Care Services ETF's net income of --. Notably, State Street SPDR S&P Biotech ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Biotech ETF is -- versus -- for State Street SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIState Street SPDR S&P Biotech ETF-- -- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- --
-
Which has Higher Returns XBI or XLV?
State Street Health Care Select Sector SPDR ETF has a net margin of -- compared to State Street SPDR S&P Biotech ETF's net margin of --. State Street SPDR S&P Biotech ETF's return on equity of -- beat State Street Health Care Select Sector SPDR ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBIState Street SPDR S&P Biotech ETF-- -- -- XLVState Street Health Care Select Sector SPDR ETF-- -- -- -
What do Analysts Say About XBI or XLV?
State Street SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street Health Care Select Sector SPDR ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that State Street SPDR S&P Biotech ETF has higher upside potential than State Street Health Care Select Sector SPDR ETF, analysts believe State Street SPDR S&P Biotech ETF is more attractive than State Street Health Care Select Sector SPDR ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBIState Street SPDR S&P Biotech ETF0 0 0 XLVState Street Health Care Select Sector SPDR ETF0 0 0 -
Is XBI or XLV More Risky?
State Street SPDR S&P Biotech ETF has a beta of 0.931, which suggesting that the stock is 6.918% less volatile than S&P 500. In comparison State Street Health Care Select Sector SPDR ETF has a beta of 0.656, suggesting its less volatile than the S&P 500 by 34.433%.
-
Which is a Better Dividend Stock XBI or XLV?
State Street SPDR S&P Biotech ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.03%. State Street Health Care Select Sector SPDR ETF offers a yield of 1.59% to investors and pays a quarterly dividend of $0.62 per share. State Street SPDR S&P Biotech ETF pays -- of its earnings as a dividend. State Street Health Care Select Sector SPDR ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or XLV?
State Street SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than State Street Health Care Select Sector SPDR ETF quarterly revenues of --. State Street SPDR S&P Biotech ETF's net income of -- is lower than State Street Health Care Select Sector SPDR ETF's net income of --. Notably, State Street SPDR S&P Biotech ETF's price-to-earnings ratio is -- while State Street Health Care Select Sector SPDR ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for State Street SPDR S&P Biotech ETF is -- versus -- for State Street Health Care Select Sector SPDR ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIState Street SPDR S&P Biotech ETF-- -- -- -- XLVState Street Health Care Select Sector SPDR ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
